# Amoxicillin for Pneumonia: Veterinary Use Guide Amoxicillin is a narrow-spectrum aminopenicillin antibiotic that kills susceptible bacteria by disrupting the construction of their cell wall. In [veterinary medicine](/blog/careers/veterinary-medicine-careers-from-clinical-practice-to-public-health) it is used for respiratory disease in cattle, pigs, dogs, and cats, but it is not a universal pneumonia drug. It works well against many *Pasteurella multocida*, *[Mannheimia haemolytica](/knowledge/bacteria/livestock-bacteria/mannheimia-haemolytica)*, *[Actinobacillus pleuropneumoniae](/knowledge/bacteria/livestock-bacteria/actinobacillus-pleuropneumoniae)*, and *Streptococcus suis* infections, and it works poorly against bacteria that produce beta-lactamase enzymes, which includes most *Klebsiella pneumoniae*, *Escherichia coli*, and *Staphylococcus* species. Amoxicillin is a prescription product in every species where it is used, and it is given by injection or by mouth depending on the labeled formulation. This article is educational and is not a substitute for veterinary diagnosis or treatment. ## At a Glance | Feature | Detail | |--|--| | Active ingredient | Amoxicillin (aminopenicillin). Amoxicillin-clavulanate adds clavulanic acid, a beta-lactamase inhibitor | | Species and label limits | Cattle, pigs, dogs, and cats have separate labeled products. Minimum age and weight are set by each product label, not by the molecule | | How it is given | Intramuscular or subcutaneous injection (cattle and pigs), oral suspension or tablets (dogs and cats), oral powder or in-feed and in-water formulations (pigs) | | How fast it works | Blood concentrations rise within hours of injection. Clinical improvement in pneumonia is usually judged over 24 to 72 hours, not hours | | How long it lasts | Depends on formulation. A depot injection in calves produced mean residence times of roughly 16.5 hours in serum and about 29 hours in tissue cage fluid [1] | | Prescription or OTC | Prescription only in the United States. Extra-label use in food animals is restricted by federal law | | Killing style | Time-dependent. The percentage of the dosing interval that free drug stays above the minimum inhibitory concentration (T>MIC) predicts success more than peak concentration does [1][2] | ## What Amoxicillin Is and What It Treats Amoxicillin belongs to the aminopenicillin group of beta-lactam antibiotics. Beta-lactams bind penicillin-binding proteins inside the bacterial cell wall and block the cross-linking step that gives the wall its strength. The bacterium keeps trying to grow, the wall fails, and the cell lyses. This is a bactericidal mechanism, meaning the drug kills rather than merely stops growth, and it is the same basic mechanism as penicillin G and ampicillin. Amoxicillin differs from ampicillin mainly in absorption. When given by mouth, amoxicillin is absorbed more completely from the gastrointestinal tract and reaches higher blood concentrations for a given dose. That property made it the preferred oral aminopenicillin in small animal practice and the base molecule for the oral suspensions used in dogs and cats. The labeled respiratory indications differ by species and by country, so the label on the bottle matters more than the molecule name. In general terms: - **Cattle.** Amoxicillin injectable products are labeled for bovine respiratory disease (BRD) caused by susceptible *Mannheimia haemolytica* and *Pasteurella multocida*. - **Pigs.** Amoxicillin injectable and oral products are labeled for respiratory disease associated with susceptible *Actinobacillus pleuropneumoniae*, *Pasteurella multocida*, *[Haemophilus parasuis](/knowledge/bacteria/livestock-bacteria/haemophilus-parasuis-glaessers-disease-pigs)*, and *Streptococcus suis*. - **Dogs.** Amoxicillin and amoxicillin-clavulanate oral products are labeled for susceptible respiratory infections, including pneumonia secondary to other disease. - **Cats.** Similar oral products are labeled for susceptible respiratory tract infections, though feline pneumonia is often viral or *Mycoplasma*-driven and amoxicillin alone may not be the right choice. The important limitation is that a label indication describes bacteria that are susceptible. It does not promise that the bacteria in a particular animal are susceptible. That distinction drives most of the clinical decision-making below. ## How Amoxicillin Kills Bacteria: The Time-Dependent Rule Most antibiotics fall into one of two pharmacodynamic categories. Concentration-dependent drugs, such as the fluoroquinolones and aminoglycosides, kill better as the peak drug concentration rises relative to the MIC. Time-dependent drugs, including all the beta-lactams, kill better the longer the drug concentration stays above the MIC during each dosing interval. For amoxicillin, the relevant parameter is T>MIC, the fraction of the dosing interval in which free drug concentration exceeds the MIC of the target pathogen. A 2015 study by Lees and colleagues measured this directly for the two major bovine respiratory pathogens [1]. The researchers established MICs and time-kill curves for *Mannheimia haemolytica* and *Pasteurella multocida*, then modeled the data with a sigmoidal Emax equation to define three efficacy levels: bacteriostasis, bactericidal activity (a 3-log10 reduction in bacterial counts), and a 4-log10 reduction. For *M. haemolytica*, the mean AUC(0-24h)/MIC values needed for those three levels were 29.1, 57.3, and 71.5 hours. For *P. multocida* they were 28.1, 44.9, and 59.5 hours. The same study measured amoxicillin pharmacokinetics in calves after a 15 mg/kg intramuscular depot injection and found Cmax/MIC ratios of 13.9:1 and 25.2:1, AUC(0-infinity)/MIC ratios of 179 and 325 hours, and T>MIC values of 40.3 and 57.6 hours for *P. multocida* and *M. haemolytica* respectively [1]. Those T>MIC numbers are the practical heart of amoxicillin dosing. A single depot injection kept drug above the MIC for roughly 40 to 58 hours in that calf model, which is why long-acting formulations can be given less often than the serum half-life alone would suggest. The tissue cage fluid data reinforce the point. Mean residence time was 16.5 hours in serum but 29.6 hours in inflamed exudate and 29.0 hours in noninflamed transudate [1]. Drug that partitions into inflamed lung tissue and stays there supports the time-above-MIC effect at the site of infection, not just in blood. A separate study by Tanigawa and Sawada evaluated amoxicillin against *Actinobacillus pleuropneumoniae* in both in vitro culture and experimentally infected pigs [2]. In vitro, growth was inhibited when amoxicillin concentration was above the MIC (1.28 x MIC) and the duration of inhibition was directly proportional to the time of exposure. Below the MIC (0.25 x MIC), growth was not inhibited at all. In the live pig model, a sustained-release injectable formulation was given at 7.5 mg/kg/day and 15 mg/kg/day after clinical signs appeared at 6 hours post-infection [2]. The pattern matched the in vitro result: efficacy tracked exposure time, not peak height. The clinical consequence is straightforward. Cutting a dose or stretching an interval reduces T>MIC and can turn a bactericidal regimen into a bacteriostatic one or a failure. Giving a higher peak for a shorter time does not compensate, because the killing mechanism is saturated once the concentration is a few multiples above the MIC. ## What Amoxicillin Does Not Cover Amoxicillin is vulnerable to beta-lactamase enzymes, which are produced by many clinically important bacteria. When a beta-lactamase encounters amoxicillin, it hydrolyzes the beta-lactam ring and the drug becomes inactive. This is the single most important reason amoxicillin fails in pneumonia cases where the pathogen was not what the clinician expected. The resistance pattern shows up clearly in surveillance data. The VetPath program collected respiratory pathogens from diseased cattle and pigs across Europe and tested them centrally by broth microdilution [3][4]. In the 2009 to 2012 collection, resistance to amoxicillin/clavulanic acid, ceftiofur, enrofloxacin, florfenicol, tulathromycin, tiamulin, and tilmicosin was absent or below 2 percent in pig isolates, and cattle isolates were generally highly susceptible to most antibiotics tested [3]. The 2002 to 2006 VetPath collection found that all 231 *P. multocida* and 138 *M. haemolytica* isolates from cattle were susceptible to amoxicillin/clavulanic acid, ceftiofur, enrofloxacin, and trimethoprim/sulfamethoxazole [4]. Those are encouraging numbers for the classic respiratory pathogens, and they explain why amoxicillin-clavulanate retains a strong position in bovine and porcine respiratory therapy. The picture changes sharply for Gram-negative enteric organisms. A 2024 study of *Enterobacter hormaechei* isolated from cattle with bovine respiratory disease found high resistance to amoxicillin, ampicillin, amikacin, nalidixic acid, and ceftazidime, with high susceptibility to azithromycin, levofloxacin, gentamicin, ofloxacin, cefepime, ceftriaxone, cefotaxime, nitrofurantoin, and ciprofloxacin [5]. *Enterobacter* is not a classic BRD pathogen, but it appears often enough in treatment failures that it belongs on the differential list. *Klebsiella pneumoniae* is the clearest example of a beta-lactamase problem. A 2011 study of *K. pneumoniae* from diseased swine in southwestern China found that 75.8 to 100 percent of isolates were resistant to beta-lactams, and that bla(TEM-1) was present in 100 percent of the 58 isolates tested [6]. Four novel OKP beta-lactamase variants were identified among isolates resistant to ampicillin, amoxicillin, oxacillin, cefalexin, and cefadroxil [6]. A 2025 study of *K. pneumoniae* from respiratory-diseased pet cats in Iraq reported that the isolates were significantly resistant to amoxicillin along with clarithromycin, clindamycin, cefixime, chloramphenicol, erythromycin, cephalexin, cefadroxil, azithromycin, and nalidixic acid, while showing higher sensitivity to ceftiofur, ciprofloxacin, cefepime, amikacin, gentamicin, cefotaxime, meropenem, ceftazidime, ceftriaxone, doxycycline, imipenem, and tetracycline [7]. A 2025 study of resistant respiratory isolates from human sputum samples also found *K. pneumoniae* resistant to amoxicillin at 30 micrograms [8]. The pattern is consistent across species: when the pathogen is *Klebsiella*, *E. coli*, *Enterobacter*, or a beta-lactamase-producing *Staphylococcus*, amoxicillin alone is the wrong drug. The 2025 case report of necrotizing *E. coli* pneumonia in a dog is a useful illustration. The dog had been treated with doxycycline and amoxicillin-clavulanate without resolution, and culture of a bronchoalveolar lavage sample isolated *E. coli* that was susceptible to enrofloxacin [9]. The dog required surgical resection of a lung lobe in addition to appropriate antibiotics, and survived to discharge after 38 days [9]. That case does not prove amoxicillin-clavulanate is always inadequate for *E. coli*, but it shows how a beta-lactamase-producing Gram-negative can defeat a beta-lactam-based regimen. *Mycoplasma* species are another gap. Mycoplasmas lack a cell wall entirely, so beta-lactams have no target. A 2025 case series of 13 dogs with suspected [canine infectious respiratory disease complex](/knowledge/veterinary-medicine/clinical-internal-medicine/canine-respiratory-disease-complex-diagnostic-therapeutic-approach) pneumonia found *Mycoplasma cynos* as the sole pathogen in 8 dogs and co-occurring with *[Bordetella bronchiseptica](/knowledge/bacteria/pet-bacteria/bordetella-bronchiseptica)* in 5 dogs [10]. Doxycycline, amoxicillin-clavulanic acid, and fluoroquinolones were frequently prescribed for two weeks or longer, and 12 of 13 dogs survived [10]. The authors noted that *M. cynos* may be an important agent in some CIRDC clusters [10]. The clinical takeaway is that when *Mycoplasma* is suspected, a drug with activity against cell-wall-free organisms, such as doxycycline or a fluoroquinolone, is the logical choice, and amoxicillin contributes nothing against that component even if it covers a concurrent bacterium. ## Amoxicillin Versus Amoxicillin-Clavulanate These are two different drugs in practice, even though they share the same active beta-lactam. Amoxicillin alone is the base molecule. Amoxicillin-clavulanate adds clavulanic acid, a beta-lactamase inhibitor that binds and inactivates many beta-lactamase enzymes before they can destroy amoxicillin. Clavulanate has negligible antibacterial activity of its own. Its only job is to protect the amoxicillin. The addition of clavulanate widens the spectrum to include beta-lactamase-producing *Staphylococcus aureus*, *E. coli*, *Klebsiella*, and *Pasteurella* species that would otherwise be resistant. That is why the VetPath surveillance programs reported resistance to amoxicillin/clavulanic acid as absent or below 2 percent in pig respiratory isolates, while other studies reported substantial amoxicillin resistance in the same pathogen groups [3][4]. The trade-off is cost, and in food animals, withdrawal time. Clavulanate adds expense, and the combination product may have different label withdrawal periods than amoxicillin alone. In pigs, a 1999 field study by Markowska-Daniel and Pejsak evaluated amoxicillin-clavulanate in weaned pigs with mixed respiratory tract infections and found positive effects in the majority of treated pigs, lower production losses than controls treated with oxytetracycline, a significantly lower death ratio, and higher body weight gain at 30 days after therapy [11]. The combination was given because the infections were mixed, and mixed infections are exactly the situation where clavulanate earns its place. For a clinician, the decision rule is simple. If the pathogen is known or strongly suspected to be a non-beta-lactamase producer, such as *M. haemolytica* or *P. multocida* in cattle, amoxicillin alone is usually sufficient and cheaper. If the pathogen is unknown, if the case has failed amoxicillin, or if the likely pathogen is a beta-lactamase producer, amoxicillin-clavulanate is the more defensible choice, or a different drug class entirely. ## Species by Species: Where Amoxicillin Fits ### Cattle Bovine respiratory disease is the most common reason amoxicillin injectables are used in cattle. The classic bacterial pathogens are *Mannheimia haemolytica*, *Pasteurella multocida*, and *[Histophilus somni](/knowledge/bacteria/livestock-bacteria/histophilus-somni)*. Surveillance data from the VetPath program found these organisms to be highly susceptible to amoxicillin/clavulanic acid and other beta-lactams in the 2002 to 2006 and 2009 to 2012 collections [3][4]. Amoxicillin is not always first-line for BRD, however. The 2015 pharmacokinetic and pharmacodynamic modeling by Lees and colleagues showed that a single 15 mg/kg intramuscular depot injection achieved T>MIC values of 40.3 and 57.6 hours for *P. multocida* and *M. haemolytica* respectively, with Monte Carlo simulation predicting a 90 percent target attainment rate for bactericidal effect from a single dose [1]. That supports amoxicillin as a reasonable first choice when the pathogen profile is favorable and the case is uncomplicated. Resistance is not static. A 2009 study of 229 *M. haemolytica* isolates from cattle with bovine respiratory disease collected between 1984 and 2006 found that 49.8 percent were resistant to at least one agent, with resistance rates of 16.6 percent for amoxicillin and 19.2 percent for ampicillin [12]. That is a meaningful proportion of isolates, and it argues for culture and susceptibility testing when treatment fails or when the herd history suggests prior beta-lactam use. A 2023 study of subclinical pneumonia in male dairy calves used quick thoracic ultrasonography to track lung consolidation [13]. Initial therapy with tulathromycin followed by doxycycline appeared ineffective, and the proportion of calves with pneumonia rose to 43.8 percent by week 4. At that point treatment with amoxicillin resulted in a cure risk of 52.7 percent [13]. That figure is a useful reality check. Even when amoxicillin is the right drug class, cure is not guaranteed, and roughly half the calves in that cohort did not resolve on amoxicillin alone. ### Pigs Porcine pneumonia involves a different pathogen mix. *Actinobacillus pleuropneumoniae*, *Pasteurella multocida*, *Haemophilus parasuis*, *Streptococcus suis*, and *Bordetella bronchiseptica* are the common players. Amoxicillin is labeled for several of these, and the pharmacodynamic work by Tanigawa and Sawada confirmed that amoxicillin kills *A. pleuropneumoniae* in a time-dependent manner, with growth inhibition proportional to exposure time above the MIC [2]. Resistance trends in pigs are concerning. A 2012 retrospective study of 992 *A. pleuropneumoniae* isolates from pigs in Italy collected between 1994 and 2009 found a significant increasing trend in resistance to amoxicillin, amoxicillin/clavulanic acid, ampicillin, cefquinome, cotrimoxazole, penicillin G, and tilmicosin, while resistance to gentamicin and marbofloxacin decreased [14]. Most isolates retained high susceptibility to amphenicols, fluoroquinolones, and ceftiofur, but high rates of resistance were observed for potentiated sulfa drugs, tetracyclines, and penicillins, which are the antimicrobials currently recommended for pig pleuropneumonia therapy [14]. That is a direct warning that amoxicillin's position in swine respiratory medicine is eroding. A 2017 study of 62 *P. multocida* strains from the lungs of diseased pigs in Taiwan found resistance ratios above 40 percent for all 13 antimicrobials tested except cefazolin, with the highest resistance (100 percent) for kanamycin, erythromycin, and tylosin [15]. The majority of isolates were serotype D:L6, and resistance rates were higher in that serotype than in A:L3 for all tested antimicrobials except tylosin and tilmicosin [15]. Amoxicillin was among the tested agents, and the overall pattern confirms that susceptibility testing is not optional in modern swine practice. *Streptococcus suis* is another porcine respiratory pathogen with zoonotic importance. A 2013 study evaluated nisin, a bacteriocin, against *S. suis* serotype 2 and found MICs of 1.25 to 5 micrograms per milliliter and MBCs of 5 to 10 micrograms per milliliter, with rapid bactericidal activity and synergy with conventional antibiotics [16]. The study exists because increased antibiotic resistance in *S. suis* has been reported worldwide [16]. Amoxicillin retains activity against many *S. suis* isolates, but the resistance trend means it should not be assumed. ### Dogs Canine pneumonia is often secondary to another problem: aspiration, megaesophagus, viral respiratory disease, or immunosuppression. The bacterial pathogens are frequently *Bordetella bronchiseptica*, *Streptococcus* species, *E. coli*, *Pasteurella*, and *Mycoplasma*. Amoxicillin alone is rarely the first choice for canine pneumonia because the pathogen mix so often includes beta-lactamase producers or cell-wall-free organisms. Amoxicillin-clavulanate is more commonly used, and even then it may not be enough. The 2025 *Mycoplasma cynos* case series found that doxycycline, amoxicillin-clavulanic acid, and fluoroquinolones were all used, and 12 of 13 dogs survived [10]. The authors did not attribute survival to any single drug, and the presence of *Mycoplasma* as the sole pathogen in 8 dogs means the amoxicillin component was not the active drug in those cases. The 2025 necrotizing *E. coli* pneumonia case report is instructive for a different reason. The dog had been treated with amoxicillin-clavulanate and doxycycline before presentation, and the *E. coli* isolated was susceptible to enrofloxacin [9]. The case required surgery and 38 days to radiographic resolution [9]. When a dog with pneumonia does not improve on a beta-lactam, the next step is usually culture and susceptibility testing rather than a higher dose of the same drug. A 2026 case report of *Candida glabrata* aspiration pneumonia in a dog with megaesophagus described prior treatment with omeprazole and amoxicillin-clavulanic acid for 2.5 weeks [17]. The dog deteriorated despite fluconazole and was euthanized, with *C. glabrata* and polymicrobial infection identified on airway culture and postmortem lung culture [17]. The clinical message from the authors was that *Candida* should be considered in dogs with aspiration pneumonia, especially those treated with antimicrobials and gastroprotectants [17]. Amoxicillin-clavulanate did not cause the fungal infection, but broad antimicrobial exposure in a patient with aspiration risk is a recognized setup for opportunistic yeast. ### Cats Feline pneumonia is less common than canine pneumonia and is more often viral or *Mycoplasma*-associated. *Klebsiella pneumoniae* is an emerging concern. A 2025 study of 127 cats with respiratory signs in Iraq found that 26.77 percent of nasal swabs were positive for *K. pneumoniae*, and the isolates were significantly resistant to amoxicillin along with several other drugs [7]. The same isolates showed higher sensitivity to ceftiofur, ciprofloxacin, cefepime, amikacin, gentamicin, cefotaxime, meropenem, ceftazidime, ceftriaxone, doxycycline, imipenem, and tetracycline [7]. For a cat with suspected bacterial pneumonia, amoxicillin alone is a weak choice when *Klebsiella* is on the differential. ## Species Summary Table | Species | Typical respiratory indication | Is amoxicillin first-line? | |--|--|--| | Cattle | Bovine respiratory disease caused by susceptible *M. haemolytica* and *P. multocida* | Sometimes. Reasonable when the pathogen profile is favorable and the case is uncomplicated. Resistance to amoxicillin in *M. haemolytica* was 16.6 percent in one 1984-2006 survey [12] | | Pigs | Respiratory disease associated with susceptible *A. pleuropneumoniae*, *P. multocida*, *H. parasuis*, and *S. suis* | Less often than in the past. Resistance trends in *A. pleuropneumoniae* and *P. multocida* are rising [15][14]. Amoxicillin-clavulanate is often preferred for mixed infections [11] | | Dogs | Susceptible respiratory infections, often secondary to aspiration or viral disease | Rarely alone. Amoxicillin-clavulanate is more common, and *Mycoplasma* or Gram-negative involvement often requires a different drug [10][9] | | Cats | Susceptible respiratory tract infections | Rarely alone. *K. pneumoniae* resistance to amoxicillin is documented in respiratory-diseased cats [7] | ## How Amoxicillin Is Given The route depends on the species and the formulation. **Injectable formulations.** Cattle and pigs receive amoxicillin by intramuscular or subcutaneous injection, often as a long-acting depot product. The 2015 calf study used a 15 mg/kg intramuscular depot injection and measured mean residence times of 16.5 hours in serum and about 29 hours in tissue cage fluid [1]. The 2003 pig study used a sustained-release injectable at 7.5 mg/kg/day and 15 mg/kg/day [2]. Depot formulations are designed to maintain T>MIC over a long interval, which is why they can be dosed less frequently than immediate-release products. **Oral suspensions and tablets.** Dogs and cats receive amoxicillin or amoxicillin-clavulanate by mouth. Oral absorption of amoxicillin is good on an empty stomach, and food can reduce absorption of some formulations. Giving the dose with a small amount of food is a common compromise when the animal will not take it otherwise, but the label directions should be followed. **In-feed and in-water formulations.** Pigs may receive amoxicillin through medicated feed or water. This route is convenient for groups but makes individual dose control difficult, and sick pigs often eat and drink less, which reduces the dose they actually receive. **Duration.** Pneumonia treatment typically runs for 5 to 14 days, or longer for severe or complicated cases. The *Mycoplasma cynos* case series used doxycycline, amoxicillin-clavulanate, and fluoroquinolones for two weeks or longer [10]. The necrotizing *E. coli* case required 38 days to radiographic resolution [9]. Short courses risk relapse, and long courses increase the risk of resistance and adverse effects. ## Side Effects and What to Do About Them Amoxicillin is generally well tolerated, but several adverse effects are recognized. **Gastrointestinal upset.** Vomiting, diarrhea, and reduced appetite are the most common complaints in dogs and cats on oral amoxicillin. Giving the dose with a small meal often reduces nausea. Persistent vomiting or bloody diarrhea warrants stopping the drug and calling the veterinarian. **Injection site reactions.** Intramuscular and subcutaneous injections can cause local swelling, pain, and inflammation. Depot formulations are more likely to cause this because they stay in the tissue longer. Rotating injection sites and avoiding repeated injection into the same spot reduces the problem. **Allergic reactions.** True penicillin allergy is uncommon in animals but can occur. Signs include facial swelling, hives, and in severe cases anaphylaxis. Any suspected allergic reaction is an emergency. **Dysbiosis and opportunistic infection.** Broad antimicrobial exposure can disrupt normal bacterial populations and allow overgrowth of resistant organisms or fungi. The 2026 *Candida glabrata* case in a dog with megaesophagus followed 2.5 weeks of amoxicillin-clavulanate and omeprazole [17]. The authors recommended considering *Candida* in dogs with aspiration pneumonia, especially those treated with antimicrobials and gastroprotectants [17]. **Resistance selection.** Every course of amoxicillin exerts selective pressure. The rising resistance trends in *A. pleuropneumoniae* and *P. multocida* are partly a consequence of widespread beta-lactam use in food animals [15][14]. Using amoxicillin only when the pathogen is likely susceptible is both good stewardship and good individual patient care. ## Which Animals Should Not Receive Amoxicillin Amoxicillin should not be given to animals with a known penicillin or cephalosporin allergy. Cross-reactivity between beta-lactam classes is possible, so a documented cephalosporin reaction is a reason for caution. It should not be used for infections known or strongly suspected to be caused by beta-lactamase-producing bacteria, *Mycoplasma* species, or fungi. In those cases the drug is not just ineffective, it delays effective treatment. In food animals, amoxicillin use is governed by label withdrawal times and by federal restrictions on extra-label use of medically important antimicrobials. The withdrawal time on the specific product label is the legal requirement, and it differs between amoxicillin alone and amoxicillin-clavulanate, and between injectable and oral formulations. A veterinarian familiar with the current regulations should be consulted before any extra-label use in a food-producing animal. In very young animals, the label minimum age and weight must be respected. Neonates have immature hepatic and renal clearance, and the labeled limits exist for a reason. ## Interactions Amoxicillin has relatively few clinically significant drug interactions compared with some other antibiotic classes. **Bacteriostatic antibiotics.** Combining amoxicillin with a bacteriostatic drug such as tetracycline or chloramphenicol can theoretically reduce efficacy, because bacteriostatic agents slow bacterial growth and beta-lactams kill growing bacteria. The clinical significance of this interaction is debated, and the combination is sometimes used intentionally in mixed infections. **Probenecid.** Probenecid blocks renal tubular secretion of penicillins and prolongs their blood concentrations. This interaction is well known in human medicine and can occur in animals, though it is rarely used deliberately in veterinary practice. **Antacids and gastric acid suppressants.** Reduced gastric acidity can alter absorption of some oral beta-lactams. The clinical relevance for amoxicillin is modest, but it is one reason to separate dosing from antacid administration when possible. **Other nephrotoxic drugs.** Amoxicillin is not strongly nephrotoxic on its own, but combining it with a nephrotoxic drug in a dehydrated animal can worsen renal function indirectly. ## How Amoxicillin Compares With Alternatives **Amoxicillin-clavulanate.** The clavulanate component extends coverage to beta-lactamase-producing bacteria. It is more expensive and may have different withdrawal times in food animals. It is the preferred beta-lactam when the pathogen profile is unknown or includes beta-lactamase producers [3][4]. **Tetracyclines (doxycycline, oxytetracycline).** Doxycycline covers *Mycoplasma*, *Bordetella*, and many *Pasteurella* species, and it is commonly used in canine and bovine respiratory disease. It is bacteriostatic, so the pharmacodynamic target is different from amoxicillin's. In the 2023 calf study, initial therapy with tulathromycin followed by doxycycline appeared ineffective, and amoxicillin later achieved a 52.7 percent cure risk [13]. In the 1999 pig study, amoxicillin-clavulanate outperformed oxytetracycline on production outcomes [11]. **Fluoroquinolones (enrofloxacin, marbofloxacin).** These are concentration-dependent bactericidal drugs with broad Gram-negative coverage, including *E. coli* and *K. pneumoniae*. They are often the choice when a beta-lactam has failed. The necrotizing *E. coli* pneumonia case was treated with enrofloxacin after amoxicillin-clavulanate and doxycycline failed [9]. Fluoroquinolone resistance is a growing concern, and these drugs are typically reserved for cases where culture supports them. **Macrolides (tulathromycin, tilmicosin, tylosin).** Macrolides are time-dependent and concentrate in lung tissue. They are commonly used in bovine and porcine respiratory disease. The 2023 calf study used tulathromycin as initial therapy, though it appeared ineffective in that cohort [13]. Resistance to macrolides in pig *P. multocida* isolates was high in the 2017 Taiwan study, with 100 percent resistance to erythromycin and tylosin [15]. **Cephalosporins (ceftiofur).** Third-generation cephalosporins have broad Gram-negative coverage and are resistant to many beta-lactamases. In the 2017 Taiwan study, cefazolin was the only drug among 13 tested to which *P. multocida* resistance was below 40 percent [15]. Ceftiofur is a common choice in food animals when a beta-lactam is needed but amoxicillin resistance is suspected. **Potentiated sulfonamides.** These are inexpensive and broad-spectrum, but resistance in *A. pleuropneumoniae* is high, and the 2012 Italian study identified potentiated sulfa drugs among the antimicrobials with high resistance rates in pig pleuropneumonia [14]. ## Questions to Ask a Veterinarian 1. What pathogen do you suspect, and is amoxicillin likely to cover it? 2. Has a culture and susceptibility test been submitted, and when will results be available? 3. Should we use amoxicillin alone or amoxicillin-clavulanate? 4. What is the correct dose and interval for this specific product and this specific animal? 5. How long should the course run, and what clinical signs should I watch for to know it is working? 6. What side effects should I watch for, and when should I call you? 7. If this animal is a food producer, what is the withdrawal time on this product label? 8. What is the plan if the animal does not improve in 48 to 72 hours? ## Clinical Relevance, Limitations and Common Mistakes Amoxicillin remains a useful drug for pneumonia when the pathogen is susceptible and the pharmacodynamics are respected. Its time-dependent killing means that maintaining T>MIC matters more than achieving a high peak, and long-acting formulations are designed around that principle [1][2]. The drug's weakness is beta-lactamase susceptibility, which makes it unreliable against *Klebsiella*, *E. coli*, *Enterobacter*, and beta-lactamase-producing *Staphylococcus* species [5][7][6]. *Mycoplasma* species are intrinsically resistant because they lack a cell wall [10]. The most common mistakes in practice are predictable. Using amoxicillin alone when the pathogen is a beta-lactamase producer is the first. Confusing amoxicillin with amoxicillin-clavulanate is the second, and it leads to under-treatment of mixed infections. Under-dosing or stretching the interval is the third, and it undermines the time-dependent killing mechanism. Skipping culture and susceptibility testing when the first course fails is the fourth, and it delays effective treatment. The 2023 calf study is a reminder that even appropriate amoxicillin therapy achieved a cure risk of only 52.7 percent in a cohort with subclinical pneumonia [13]. Response to treatment is not guaranteed, and failure should prompt reassessment rather than repetition. Resistance trends in food animals deserve specific attention. The 2012 Italian study found a significant increasing trend in *A. pleuropneumoniae* resistance to amoxicillin, amoxicillin-clavulanate, ampicillin, and penicillin G over a 15-year period [14]. The 2017 Taiwan study found resistance ratios above 40 percent for all tested antimicrobials except cefazolin in pig *P. multocida* isolates [15]. The 2009 *M. haemolytica* study found 16.6 percent amoxicillin resistance in isolates collected between 1984 and 2006 [12]. These numbers do not mean amoxicillin is useless, but they mean it should not be used reflexively. Individual cases vary, and the decision to use amoxicillin for any particular animal requires a veterinarian who can examine the patient, consider the history, and interpret diagnostic results. ## Frequently Asked Questions ### Is amoxicillin effective against all types of pneumonia in animals? No. Amoxicillin works against susceptible *Pasteurella*, *Mannheimia*, *Actinobacillus*, and *Streptococcus* species, but it fails against beta-lactamase-producing bacteria such as *Klebsiella* and *E. coli*, and it has no activity against *Mycoplasma* because those organisms lack a cell wall. ### What is the difference between amoxicillin and amoxicillin-clavulanate? Amoxicillin-clavulanate adds clavulanic acid, which blocks many beta-lactamase enzymes and protects the amoxicillin. The combination covers beta-lactamase-producing bacteria that amoxicillin alone cannot kill. ### Why does amoxicillin sometimes fail even when the bacteria should be susceptible? Time-dependent killing means the drug must stay above the minimum inhibitory concentration for enough of the dosing interval. Under-dosing, missed doses, poor absorption, or reduced blood flow to infected lung tissue can all reduce T>MIC and cause treatment failure. ### Can amoxicillin be used to treat pneumonia in dogs and cats? It can be used for susceptible respiratory infections, but it is rarely the first choice for pneumonia because the pathogen mix often includes *Mycoplasma*, *Bordetella*, or Gram-negative bacteria that amoxicillin does not cover well. Amoxicillin-clavulanate or a different drug class is often more appropriate. ### How long does it take for amoxicillin to work on pneumonia? Clinical improvement is usually judged over 24 to 72 hours. Blood concentrations rise within hours of injection, but lung tissue healing and bacterial clearance take longer. If there is no improvement in 48 to 72 hours, the treatment plan should be reassessed. ### Is amoxicillin safe for pregnant or nursing animals? Beta-lactams are generally considered safe in pregnancy, but the specific product label should be consulted. Some formulations are not labeled for use in pregnant animals, and a veterinarian should make the risk-benefit assessment. ### Can I use amoxicillin left over from a previous prescription? No. Leftover antibiotics may be expired, may be the wrong dose for the current animal, and may not be the right drug for the current infection. Using leftover antibiotics also contributes to resistance. ### What should I do if my animal does not improve on amoxicillin? Call the veterinarian. Failure to improve in 48 to 72 hours suggests the pathogen is not susceptible, the dose is inadequate, or there is a complicating factor such as an abscess, foreign body, or fungal infection. Culture and susceptibility testing is usually the next step. ## Related Articles - [How Does A Dog Get Pneumonia](/knowledge/veterinary-medicine/clinical-methods/how-does-a-dog-get-pneumonia) - [Clavamox Amoxicillin-Clavulanate: Feline Respiratory and Skin Infection Dose](/knowledge/veterinary-medicine/calculators-clinical-tools/clavamox-amoxicillin-clavulanate-feline-respiratory-and-skin-infection-dose) - [Amoxicillin Dog Cat Dose: Broad-Spectrum Antibiotic Weight-Based Guide](/knowledge/veterinary-medicine/calculators-clinical-tools/amoxicillin-dog-cat-dose-broad-spectrum-antibiotic-weight-based-guide) - [Calf Pneumonia: Clinical Scoring, Diagnostics, Treatment, and Ventilation Correction](/knowledge/veterinary-medicine/clinical-methods/calf-pneumonia-clinical-scoring-diagnostics-treatment-ventilation-correction) - [Mycoplasma hyopneumoniae and Enzootic Pneumonia in Pigs: Chronic Cough and Diagnosis](/knowledge/bacteria/livestock-bacteria/mycoplasma-hyopneumoniae-enzootic-pneumonia-pigs) - [Bacterial Pneumonia in Feedlot Cattle: Pathogens, Risk Factors, and Treatment Protocols](/knowledge/bacteria/livestock-bacteria/bacterial-pneumonia-feedlot-cattle-pathogens-treatment) - [Amoxicillin for UTI: Veterinary Use and Dosing](/knowledge/veterinary-medicine/pet-medication-guide/amoxicillin-for-uti-veterinary-use-and-dosing) - [Amoxicillin Side Effects in Dogs and Cats](/knowledge/veterinary-medicine/clinical-pharmacology/amoxicillin-side-effects-in-dogs-and-cats) - [Amoxicillin vs Amoxicillin-Clavulanate: Key Differences](/knowledge/veterinary-medicine/clinical-pharmacology/amoxicillin-vs-amoxicillin-clavulanate-key-differences) ## Sources 1. [Pharmacokinetic/pharmacodynamic integration and modelling of amoxicillin for the calf pathogens Mannheimia haemolytica and Pasteurella multocida.](https://pubmed.ncbi.nlm.nih.gov/25669418/) 2. [Exposure time-dependent bactericidal activities of amoxicillin against Actinobacillus pleuropneumoniae; an in vitro and In vivo pharmacodynamic model.](https://pubmed.ncbi.nlm.nih.gov/14633197/) 3. [Monitoring of antimicrobial susceptibility of respiratory tract pathogens isolated from diseased cattle and pigs across Europe, 2009-2012: VetPath results.](https://pubmed.ncbi.nlm.nih.gov/27102206/) 4. [Antimicrobial susceptibility monitoring of respiratory tract pathogens isolated from diseased cattle and pigs across Europe: the VetPath study.](https://pubmed.ncbi.nlm.nih.gov/24837878/) 5. [Molecular detection of Enterobacter hormaechei in bovine respiratory disease.](https://pubmed.ncbi.nlm.nih.gov/39834564/) 6. [Phenotypic and genotypic characterization of β-lactam resistance in Klebsiella pneumoniae isolated from swine.](https://pubmed.ncbi.nlm.nih.gov/21035968/) 7. [Phenotypic and molecular phylogeny of Klebsiella pneumoniae isolated from respiratory-diseased pet cats in Iraq.](https://pubmed.ncbi.nlm.nih.gov/41069728/) 8. [Synergistic Antibacterial Activity of Azithromycin-Loaded Chitosan Nanoparticles Alone and in Combination with Cetirizine Dihydrochloride Against Resistant Isolates of Respiratory Tract Infections.](https://pubmed.ncbi.nlm.nih.gov/41148684/) 9. [Necrotizing E. coli pneumonia with subsequent pneumothorax in a dog: a case report.](https://pubmed.ncbi.nlm.nih.gov/41049142/) 10. [Mycoplasma cynos-Associated Canine Infectious Respiratory Disease Complex Pneumonia in 13 Dogs.](https://pubmed.ncbi.nlm.nih.gov/41178398/) 11. [Efficacy of a combination of amoxicillin and clavulanic acid in the treatment of pneumonia of pigs.](https://pubmed.ncbi.nlm.nih.gov/10666934/) 12. [Antimicrobial resistance and genetic characterization of fluoroquinolone-resistant Mannheimia haemolytica isolates from cattle with bovine pneumonia.](https://pubmed.ncbi.nlm.nih.gov/19428195/) 13. [Dynamics of subclinical pneumonia in male dairy calves in relation to antimicrobial therapy and production outcomes.](https://pubmed.ncbi.nlm.nih.gov/36357203/) 14. [Antimicrobial resistance of Actinobacillus pleuropneumoniae isolated from swine.](https://pubmed.ncbi.nlm.nih.gov/22104584/) 15. [Antimicrobial susceptibility, serotypes and genotypes of Pasteurella multocida isolates associated with swine pneumonia in Taiwan.](https://pubmed.ncbi.nlm.nih.gov/28784694/) 16. [Antimicrobial activity of nisin against the swine pathogen Streptococcus suis and its synergistic interaction with antibiotics.](https://pubmed.ncbi.nlm.nih.gov/24096107/) 17. [Candida glabrata (Nakaseomyces glabratus) as a component of aspiration pneumonia in a dog with megaesophagus.](https://pubmed.ncbi.nlm.nih.gov/41716509/)